glp 1 eli lilly to seek approval of new GLP-1 weight-loss drug this year Eli Lilly's Trulicity nabs novel
Description
20122014 Expanded Therapeutic Options The approvals of Qsymia, Belviq, Contrave, and Saxenda broadened the treatment landscape and reinforced obesity as a chronic disease requiring evidence-based medical management
A new study published in April sheds light on the concerns of anesthesiologists across the United States related to the perioperative management of patients taking glucagon-like peptide-1 (GLP-1) agonists, a class of drugs now commonly prescribed for both diabetes and cosmetic weight loss
GLP-1s Carry Lilly
In a survey, employers told the Business Group on Health that they arent yet seeing evidence of long-term health benefits from taking GLP-1s for weight loss, leaving them unsure how to manage costs while continuing to cover them.
The weight loss platform Noom recently launched its compounded GLP-1 microdose injections that claim to promote weight loss with fewer side effects.
